profile

Floris from Blossom

I write about the science and implementation of psychedelics as medicines. Join to learn alongside me and make the future happen sooner!

Featured Post

The Bloom 145 - Flood of Psychedelic Research

The Bloom #145 Free Edition catching up Welcome to all the new readers of The Bloom. This newsletter usually goes out every week, but due to several circumstances it's only hitting your inbox now. This means there is a lot to cover, and instead of the top 3 articles from last week, I've featured 8. Outside of the lab, two more psychedelic companies have received FDA Breakthrough Designation (a fast-track for review, like the one Lykos is currently in the final stages of). Cybin is developing...

about 18 hours ago • 6 min read

The Bloom #144 Free Edition increasing access Innovation and exploration continue to be the cornerstones of our journey at Blossom. This month, I'm thrilled to unveil a new way in which you can interact with our ever-expanding database of psychedelic research. Imagine a chat interface that not only understands your inquiries but is also backed by the full depth of our research database. This is not a distant dream but a reality we're alpha-testing right now. Discover the future of research...

23 days ago • 3 min read

The Bloom #143 Free Edition Unus pro Omnibus, Omnes pro Uno What can we learn from 10 years of PAT in a legal and reimbursed setting? Over 1000 patients have been treated in Switzerland since 2014, though challenges remain in the execution of PAT. One challenge is the question of whether we need to have repeated dosings. For clinical trials, it's standard to ... well ... standardize. But an innovative trial in Canada has studied the effects of doing repeated doses in some participants and...

about 1 month ago • 4 min read

The Bloom #142 Free Edition PsyPal, not PayPal The FDA has received Lykos' (MAPS PBC) application and has given it priority review. This means a decision can be expected as soon as August this year. In the meantime, several research articles investigated the effects of MDMA in two very different settings. The first looked at the impact of recreational use of MDMA, showing that intention predicted long-term positive outcomes (not setting). The second study compared methylone against MDMA in...

about 1 month ago • 4 min read

The Bloom #141 Free Edition PsyPal, not PayPal You blink twice, and it's February. The past January brought great news for us Europeans, marking the launch of the PsyPal trial, a research effort spanning nine countries and funded up to the tune of €6.5 million. The research, investigating psilocybin-AT for end-of-life anxiety/depression is the first to do so outside of the scope of cancer. The funding, coming from Horizon Europe, will allow over 100 participants to join the study. Speaking of...

about 2 months ago • 3 min read

The Bloom #140 Free Edition let's get creative Research has been a bit slower in the last week(s), but that has given me more time to present a few updates on Blossom to you. Starting with 10+ new events being added to the Events database. Find all (big) psychedelic conferences in one place. Ranging from online conferences (e.g. Psychedelics Design, where I will be speaking & moderating) to international scientific gatherings (e.g. ICPR and Horizons). I've also started updating the overview...

2 months ago • 3 min read

The Bloom #139 Free Edition recovering from TBI It's been anything but a slow week in the world of psychedelics. We saw MAPS PBC transform into Lykos Therapeutics (and raising $100 million to get MDMA-AT through the FDA process), atai invested $50 million in Beckley Psytech (betting on them commercializing 5-MeO-DMT), and a widely shared study on ibogaine for TBI was published. The Stanford study brings to light an underserved population: people suffering from traumatic brain injury (TBI). In...

3 months ago • 3 min read

The Bloom #138 Free Edition the year of moving forward Happy New Year! Wow, what a year it's been for psychedelic research. I've added 288 psychedelic articles to the database and over 1000 more to the link overviews. The monthly recaps total over 16.500 words (see the one for December here). Looking up from my naval-gazing, it's also been a pivotal year with MAPS submitting the Phase III results to the FDA and 11.000 people gathering in Denver for Psychedelic Science. In 2024, we'll get more...

3 months ago • 2 min read

The Bloom #43 Thursday Free Edition penultimate newsletter of 2023 Just one more week to go, and then we can look back at another amazing year of psychedelic research findings. But before we do that, here is the latest from this week (also see my longer recap on the latest research). Happy Holidays! Floris - Founder of Blossom ps Psychedelics Today has extended the deadline for applying for their third cohort of Vital: a 12-month professional certificate training in the elements of...

3 months ago • 3 min read

The Bloom #42 Thursday Free Edition the next step in psychedelic medicine After a few weeks of slower news on the psychedelic research front, it's again moving at the speed of light. Just 2 days ago, MAPS PBC filed their application with the FDA, which is expected to result in the approval of MDMA-assisted therapy for PTSD in 10 months (though many steps will still need to be taken during this process and after it). I've also started writing more content for (paying) members exclusively,...

4 months ago • 3 min read
Share this page